ArticleClinical cancer research : an official journal of the American Association for Cancer Research2010
Epithelial membrane protein-2 is a novel therapeutic target in ovarian cancer.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 40 citations in OpenAlex.
- Cholesterol modified defense peptide as an EMP2-siRNA delivery system for synergistic immunogene therapy against breast cancer.Materials today. Bio · 2025Article
- Development of antibody drug conjugates targeting epithelial membrane protein 2-highly expressed lung cancer.Cell death & disease · 2025Article
- Tumor cell-derived EMP1 is essential for cancer-associated fibroblast infiltration in tumor microenvironment of triple-negative breast cancer.Cell death & disease · 2025Article
- EMP2 promotes hepatocellular carcinoma proliferation and invasion by activating cellular autophagy.Oncology research · 2025Article
- GrB-Fc-KS49, an anti-EMP2 granzyme B fusion protein therapeutic alters immune cell infiltration and suppresses breast cancer growth.Journal for immunotherapy of cancer · 2024Article
- The Multifaceted Role of Epithelial Membrane Protein 2 in Cancer: from Biomarker to Therapeutic Target.Biomolecules & therapeutics · 2024Review
- EMP3: A promising biomarker for tumor prognosis and targeted cancer therapy.Cancer biomarkers : section A of Disease markers · 2024Review
- Expression of EMP 1, 2, and 3 in Adrenal Cortical Neoplasm and Pheochromocytoma.International journal of molecular sciences · 2023Article
- Unraveling the structures, functions and mechanisms of epithelial membrane protein family in human cancers.Experimental hematology & oncology · 2022Review
- Expression of epithelial membrane protein (EMP) 1, EMP 2, and EMP 3 in thyroid cancer.Histology and histopathology · 2022Article
- Gene expression of Epithelial Membrane Protein 2 gene and β1-Integrin gene in patients with breast cancer.Biochemistry and biophysics reports · 2020Article
- Identification of epithelial membrane protein 2 (EMP2) as a molecular marker and correlate for angiogenesis in meningioma.Journal of neuro-oncology · 2020Article
- EMP1 Promotes the Proliferation and Invasion of Ovarian Cancer Cells Through Activating the MAPK Pathway.OncoTargets and therapy · 2020Article
- The Pivotal Roles of the Epithelial Membrane Protein Family in Cancer Invasiveness and Metastasis.Cancers · 2019Review
- Epithelial membrane protein 1 promotes tumor metastasis by enhancing cell migration via copine-III and Rac1.Oncogene · 2018Article
- Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas.Brain tumor pathology · 2018Article
- Review of the GAS3 Family of Proteins and their Relevance to Cancer.Critical reviews in oncogenesis · 2015Review
- Epithelial membrane protein-2 (EMP2) activates Src protein and is a novel therapeutic target for glioblastoma.The Journal of biological chemistry · 2014Article
- Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer.Molecular cancer therapeutics · 2014Article
- Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes.British journal of cancer · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
purposeThe tetraspan protein epithelial membrane protein-2 (EMP2) has been shown to regulate the surface display and signaling from select integrin pairs, and it was recently identified as a prognostic biomarker in human endometrial cancer. In this study, we assessed the role of EMP2 in human ovarian cancer. EXPERIMENTAL
designWe examined the expression of EMP2 within a population of women with ovarian cancer using tissue microarray assay technology. We evaluated the efficacy of EMP2-directed antibody therapy using a fully human recombinant bivalent antibody fragment (diabody) in vitro and ovarian cancer xenograft models in vivo.
resultsEMP2 was found to be highly expressed in >70% of serous and endometrioid ovarian tumors compared with nonmalignant ovarian epithelium using a human ovarian cancer tissue microarray. Using anti-EMP2 diabody, we evaluated the in vitro response of nine human ovarian cancer cell lines with detectable EMP2 expression. Treatment of human ovarian cancer cell lines with anti-EMP2 diabodies induced cell death and retarded cell growth, and these response rates correlated with cellular EMP2 expression. We next assessed the effects of anti-EMP2 diabodies in mice bearing xenografts from the ovarian endometrioid carcinoma cell line OVCAR5. Anti-EMP2 diabodies significantly suppressed tumor growth and induced cell death in OVCAR5 xenografts.
conclusionsThese findings indicate that EMP2 is expressed in the majority of ovarian tumors and may be a feasible target in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.